Artiva
formerly Artiva BiotherapeuticsIPONK Cell Therapy for Autoimmune Disease and Cancer
Artiva was founded in 2019, is headquartered in San Diego, United States, lists 51–200 employees, and has $198.0M in recorded funding across 3 rounds.
- Headquarters
- San Diego, California
- Employees
- 51–200
- Founded
- 2019
- Business Model
- B2B
- Website
- artivabio.com
- Total Funding
- $198.0M
- Last Round
- $120.0M Series BFeb 2021
- Rounds
- 3
- Type
- Public
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 3 funding rounds and 15 investors for this company. The full record is or through the API.
About
Artiva Biotherapeutics is a clinical-stage biotechnology company developing natural killer (NK) cell-based therapies for patients with autoimmune diseases and cancers. Its lead product, AlloNK, is a non-genetically modified, cryopreserved NK cell therapy designed to be produced at scale from donor cells and used in combination with B-cell targeted monoclonal antibodies. Unlike autologous CAR-T therapies, AlloNK is manufactured off-the-shelf, stored frozen, and can be administered in community settings. Artiva's manufacturing-first approach, developed in partnership with GC Cell Corporation, enables production of enough therapy to treat over 1,000 autoimmunity patients annually from its San Diego facility. The company went public on NASDAQ in July 2024.
Summary
Artiva is a Biotech company based in San Diego, United States, founded in 2019. It lists 51–200 employees. It has raised $198.0M in total across 3 rounds, most recently a $120.0M Series B round in Feb 2021. Investors include venBIO Partners, 5AM Ventures and RA Capital Management.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding & Exit History
May 2026
Sign up to see all 5 events
Funding: Seed through Series B. Amounts, valuations, and investors where available.
Investors
venBIO Partners
3 rounds
5AM Ventures
2 rounds
RA Capital Management
2 rounds
Venrock
1 round
GC LabCell Corporation
2 rounds
Green Cross Holdings Corporation
2 rounds
Acuta Capital Partners
1 round
Cormorant Asset Management
1 round
EcoR1 Capital
1 round
Franklin Templeton
1 round
Janus Henderson Investors
1 round
Logos Capital
1 round
RTW Investments
1 round
Surveyor Capital
1 round
Medivate Partners
1 round
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/artiva"><img src="https://indexed.vc/api/badge/company/artiva" alt="Artiva on Indexed.vc" width="260" height="76" /></a>